| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.49B | 7.45 | 53.21 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| EXELExelixis, Inc. | 11.82B | 44.08 | 25.05 | 18.49% | 29.63% | 31.37% | 5.36% | 0.09 |
| INBXInhibrx Biosciences, Inc. | 1.07B | 73.28 | 0.63 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.24B | 6.55 | -3.10 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.38B | 7.94 | -3.36 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ORICORIC Pharmaceuticals, Inc. | 987.53M | 10.14 | -5.54 | -33.24% | 0.01 | |||
| ZLABZai Lab Limited | 2.07B | 18.72 | -7.20 | 49.59% | -46.83% | -27.21% | 0.18 | |
| TNGXTango Therapeutics, Inc. | 1.41B | 10.44 | -8.77 | 15.17% | -151.15% | -62.81% | 0.18 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 7.87M |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 103K | 0 | 0 | 0 | 7.08M |
| COGS % of Revenue | - | - | - | - | - | - | 0.9% |
| Gross Profit | 0 | 0 | -103K | 0 | 0 | 0 | 795K |
| Gross Margin % | - | - | - | - | - | - | 0.1% |
| Gross Profit Growth % | - | - | - | 1% | - | - | - |
| Operating Expenses | 992K | 32.1M | 43.45M | 93.32M | 119.73M | 99.82M | 593.42M |
| OpEx % of Revenue | - | - | - | - | - | - | 75.37% |
| Selling, General & Admin | 509.33K | 6.99M | 10.85M | 24.28M | 31.92M | 28.53M | 69.23M |
| SG&A % of Revenue | - | - | - | - | - | - | 8.79% |
| Research & Development | 482.67K | 25.11M | 32.6M | 69.04M | 87.81M | 71.29M | 524.19M |
| R&D % of Revenue | - | - | - | - | - | - | 66.58% |
| Other Operating Expenses | 0 | -1 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -992K | -32.1M | -43.55M | -93.32M | -119.73M | -99.82M | -592.63M |
| Operating Margin % | - | - | - | - | - | - | -75.27% |
| Operating Income Growth % | - | -31.36% | -0.36% | -1.14% | -0.28% | 0.17% | -4.94% |
| EBITDA | 0 | -32.09M | -43.45M | -93.13M | -119.53M | -99.6M | -591.94M |
| EBITDA Margin % | - | - | - | - | - | - | -75.19% |
| EBITDA Growth % | - | - | -0.35% | -1.14% | -0.28% | 0.17% | -4.94% |
| D&A (Non-Cash Add-back) | 992K | 13K | 103K | 184K | 199K | 222K | 683K |
| EBIT | -992K | -32.1M | -41.66M | -93.32M | -119.73M | -75.8M | -567.6M |
| Net Interest Income | 0 | 1.37K | 1.95M | 2.96M | 7.45M | 24.61M | 26.72M |
| Interest Income | 0 | 1.37K | 1.95M | 2.96M | 7.45M | 24.61M | 27.06M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 341K |
| Other Income/Expense | 0 | -1.45M | 1.89M | 6.47M | 15.54M | 24.02M | 24.69M |
| Pretax Income | -992K | -33.55M | -41.66M | -86.85M | -104.2M | -75.8M | -567.94M |
| Pretax Margin % | - | - | - | - | - | - | -72.14% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -992K | -33.55M | -41.66M | -86.85M | -104.2M | -75.8M | -567.94M |
| Net Margin % | - | - | - | - | - | - | -72.14% |
| Net Income Growth % | - | -32.82% | -0.24% | -1.08% | -0.2% | 0.27% | -6.49% |
| Net Income (Continuing) | -992K | -33.55M | -41.66M | -86.85M | -104.2M | -75.8M | -567.94M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.01 | -0.16 | -0.19 | -0.44 | -0.48 | -0.35 | -2.11 |
| EPS Growth % | - | - | -0.19% | -1.32% | -0.09% | 0.27% | -5.03% |
| EPS (Basic) | -0.01 | -0.16 | -0.19 | -0.44 | -0.48 | -0.35 | -2.11 |
| Diluted Shares Outstanding | 183.74M | 206.67M | 217.65M | 197.89M | 216.72M | 218.88M | 268.77M |
| Basic Shares Outstanding | 183.74M | 206.67M | 217.65M | 197.89M | 216.72M | 218.88M | 268.77M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 158K | 119.89M | 220.68M | 772.07M | 667.32M | 616.43M | 526.25M |
| Cash & Short-Term Investments | 138K | 118.87M | 215.75M | 765.39M | 661.01M | 611.21M | 502.69M |
| Cash Only | 138K | 3.47M | 29.75M | 132.42M | 101.1M | 42.65M | 35.72M |
| Short-Term Investments | 0 | 115.4M | 186M | 632.97M | 559.91M | 568.56M | 466.97M |
| Accounts Receivable | 0 | 0 | 1.09M | 3.04M | 2.48M | 3.7M | 16.29M |
| Days Sales Outstanding | - | - | - | - | - | - | 755.31 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 828K | 2.92M | 0 | 3.82M | 1.52M | 7.27M |
| Total Non-Current Assets | 0 | 1.07M | 1.11M | 4.08M | 4.82M | 5.05M | 14.37M |
| Property, Plant & Equipment | 0 | 646K | 688K | 3.66M | 4.68M | 4.32M | 2.99M |
| Fixed Asset Turnover | - | - | - | - | - | - | 2.63x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 4.62M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 421K | 421K | 421K | 138K | 728K | 6.76M |
| Total Assets | 158K | 120.95M | 221.79M | 776.15M | 672.14M | 621.48M | 540.63M |
| Asset Turnover | - | - | - | - | - | - | 0.01x |
| Asset Growth % | - | 764.52% | 0.83% | 2.5% | -0.13% | -0.08% | -0.13% |
| Total Current Liabilities | 902K | 3.2M | 6.55M | 16.93M | 13.16M | 13.97M | 58.24M |
| Accounts Payable | 83K | 2.03M | 2.17M | 3.92M | 2.14M | 2.21M | 6.35M |
| Days Payables Outstanding | - | - | 7.69K | - | - | - | 327.36 |
| Short-Term Debt | 600K | 0 | 0 | 0 | 0 | 0 | 6.28M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 1000K |
| Other Current Liabilities | 0 | 11K | 3.23M | 6.17M | 3.99M | 4.35M | 14.82M |
| Current Ratio | 0.18x | 37.42x | 33.69x | 45.62x | 50.70x | 44.11x | 9.04x |
| Quick Ratio | 0.18x | 37.42x | 33.69x | 45.62x | 50.70x | 44.11x | 9.04x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 157K | 13.23M | 3.9M | 2.39M | 18.59M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 2.19M | 3.05M | 2.04M | 969K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 157K | 11.04M | 850K | 353K | 2.05M |
| Total Liabilities | 902K | 3.2M | 6.71M | 30.15M | 17.07M | 16.36M | 76.84M |
| Total Debt | 600K | 0 | 0 | 3.06M | 4.26M | 4.01M | 8.91M |
| Net Debt | 462K | -3.47M | -29.75M | -129.37M | -96.84M | -38.64M | -26.81M |
| Debt / Equity | - | - | - | 0.00x | 0.01x | 0.01x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | -1737.91x |
| Total Equity | -744K | 117.75M | 215.08M | 746M | 655.08M | 605.12M | 463.79M |
| Equity Growth % | - | 159.26% | 0.83% | 2.47% | -0.12% | -0.08% | -0.23% |
| Book Value per Share | -0.00 | 0.57 | 0.99 | 3.77 | 3.02 | 2.76 | 1.73 |
| Total Shareholders' Equity | -744K | 117.75M | 215.08M | 746M | 655.08M | 605.12M | 463.79M |
| Common Stock | 0 | 9.76M | 289.48M | 909.99M | 927.6M | 947.75M | 1.37B |
| Retained Earnings | -744K | -34.3M | -75.95M | -162.8M | -267M | -342.8M | -910.74M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 421K | 1.56M | -1.19M | -5.53M | 181K | 573K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -616K | -24.43M | -36.53M | -68.19M | -96.11M | -68M | -130.41M |
| Operating CF Margin % | - | - | - | - | - | - | -16.56% |
| Operating CF Growth % | - | -38.66% | -0.5% | -0.87% | -0.41% | 0.29% | -0.92% |
| Net Income | -992K | -33.55M | -41.66M | -86.85M | -104.2M | -75.8M | -567.94M |
| Depreciation & Amortization | 0 | 13K | 103K | 184K | 199K | 222K | 683K |
| Stock-Based Compensation | 0 | 0 | 2.2M | 9.27M | 16.29M | 19.51M | 32.27M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 110.67K | 9.57M | 715K | 4.41M | -4.95M | -12.47M | 417.07M |
| Working Capital Changes | 265.33K | -460K | 2.11M | 4.79M | -3.45M | 540K | -12.51M |
| Change in Receivables | 0 | 0 | -264K | -1.95M | 554K | -1.22M | -12.59M |
| Change in Inventory | 0 | 0 | 264K | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 34K | 1.86M | -1.79M | 70K | -1.65M |
| Cash from Investing | 0 | -115.86M | -70.32M | -454.67M | 63.46M | 8.92M | 122.7M |
| Capital Expenditures | 0 | -659K | -145K | -282K | -370K | -69K | -162K |
| CapEx % of Revenue | - | - | - | - | - | - | 0.02% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | -115.2M | 2.51M | 0 | 13K | 14K | 110.44M |
| Cash from Financing | 800K | 143.62M | 133.13M | 625.53M | 1.33M | 628K | 331K |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 800K | 128.63M | -2.52M | 625.53M | 1.33M | 628K | 0 |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -616K | -25.09M | -36.67M | -68.47M | -96.48M | -68.07M | -130.57M |
| FCF Margin % | - | - | - | - | - | - | -16.59% |
| FCF Growth % | - | -39.73% | -0.46% | -0.87% | -0.41% | 0.29% | -0.92% |
| FCF per Share | -0.00 | -0.12 | -0.17 | -0.35 | -0.45 | -0.31 | -0.49 |
| FCF Conversion (FCF/Net Income) | 0.62x | 0.73x | 0.88x | 0.79x | 0.92x | 0.90x | 0.23x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 341K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 373K |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -57.35% | -25.03% | -18.07% | -14.87% | -12.03% | -106.27% |
| Return on Invested Capital (ROIC) | - | -42.24% | -21.8% | -17.45% | -15.29% | -13.31% | -88.59% |
| Gross Margin | - | - | - | - | - | - | 10.1% |
| Net Margin | - | - | - | - | - | - | -7213.76% |
| Debt / Equity | - | - | - | 0.00x | 0.01x | 0.01x | 0.02x |
| Interest Coverage | - | - | - | - | - | - | -1737.91x |
| FCF Conversion | 0.62x | 0.73x | 0.88x | 0.79x | 0.92x | 0.90x | 0.23x |
| 2024 | |
|---|---|
| License Revenue | 2.09M |
| License Revenue Growth | - |
| 2024 | |
|---|---|
| CHINA | 5.2M |
| CHINA Growth | - |
| JAPAN | 2.7M |
| JAPAN Growth | - |
Nuvation Bio Inc. (NUVB) reported $26.7M in revenue for fiscal year 2024.
Nuvation Bio Inc. (NUVB) grew revenue by 0.0% over the past year. Growth has been modest.
Nuvation Bio Inc. (NUVB) reported a net loss of $217.5M for fiscal year 2024.
Nuvation Bio Inc. (NUVB) has a return on equity (ROE) of -106.3%. Negative ROE indicates the company is unprofitable.
Nuvation Bio Inc. (NUVB) had negative free cash flow of $190.2M in fiscal year 2024, likely due to heavy capital investments.